Department of Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Department of Clinical Genetics, Birmingham Women's and Children's Hospital NHS Trust & Birmingham Health Partners, Birmingham, UK.
Am J Med Genet A. 2021 Jan;185(1):73-82. doi: 10.1002/ajmg.a.61912. Epub 2020 Oct 14.
Hypochondroplasia (HCH) is a rare autosomal dominant skeletal dysplasia condition caused by FGFR3 mutations leading to disproportionate short stature. Classically HCH presents in toddlers or school-age children, as limb-to-trunk disproportion and is often mild and easily overlooked during infancy. We report experiences from a single-center UK HCH-cohort of 31 patients, the rate of antenatal HCH detection in our cohort (13/31, 41.9%) and describe relevant case-data for this subset of 13 patients. Inclusion criteria were patients with confirmed molecular HCH diagnosis (by age 3 years) and presenting with short long-bones or large head size on antenatal ultrasound scan. We then conducted a systematic literature review using PUBMED and MEDLINE, analyzing patients with HCH and related antenatal findings. Antenatally suspected (with subsequent molecular confirmation) HCH has been reported 15 times in the literature (2004-2019). Key markers (consistent in both groups) included reduced; femur length, humeral length and increased; biparietal diameter and head circumference. HCH is increasingly detected both antenatally and in infancy, contrary to previous descriptions. This is likely due to greater HCH awareness, improved imaging, and easier molecular testing. Thus, one should consider HCH outside the classical presenting period. Studying the natural history of younger patients with HCH is important with the advent of several targeted FGFR3 therapies currently in trials for Achondroplasia, that may soon be trialed in HCH.
软骨发育不全症(HCH)是一种罕见的常染色体显性骨骼发育不良疾病,由 FGFR3 突变引起,导致不成比例的身材矮小。HCH 通常在幼儿或学龄儿童中表现出来,表现为肢体与躯干不成比例,且在婴儿期往往较为轻微,容易被忽视。我们报告了来自英国单一中心的 31 例 HCH 患者队列的经验,我们队列中(13/31,41.9%)产前 HCH 检出率,并描述了这 13 例患者亚组的相关病例数据。纳入标准为经分子诊断(3 岁前)证实患有 HCH 且在产前超声检查中存在短肢或大头的患者。然后,我们使用 PUBMED 和 MEDLINE 进行了系统的文献综述,分析了患有 HCH 及相关产前发现的患者。文献中报道了 15 次产前怀疑(随后进行了分子证实)HCH 的病例(2004-2019 年)。关键标志物(两组均一致)包括股骨长度、肱骨长度缩短和双顶径、头围增大。HCH 无论是在产前还是在婴儿期的检出率都在增加,这与之前的描述相反。这可能是由于对 HCH 的认识提高、成像技术的改进和更易进行的分子检测所致。因此,人们应该考虑在经典发病期之外的 HCH。随着目前正在临床试验中用于治疗成骨不全症的几种靶向 FGFR3 治疗方法的出现,研究 HCH 年轻患者的自然病史非常重要,这些方法可能很快也会在 HCH 中进行试验。